CN105662903A - Skin whitening and brightening compound and application thereof - Google Patents
Skin whitening and brightening compound and application thereof Download PDFInfo
- Publication number
- CN105662903A CN105662903A CN201410655197.2A CN201410655197A CN105662903A CN 105662903 A CN105662903 A CN 105662903A CN 201410655197 A CN201410655197 A CN 201410655197A CN 105662903 A CN105662903 A CN 105662903A
- Authority
- CN
- China
- Prior art keywords
- skin
- compositions
- compound
- present
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 79
- 238000005282 brightening Methods 0.000 title claims abstract description 8
- 230000002087 whitening effect Effects 0.000 title abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 70
- 239000002537 cosmetic Substances 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims description 46
- 201000010099 disease Diseases 0.000 claims description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 36
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims description 33
- 230000000694 effects Effects 0.000 claims description 25
- 102000003425 Tyrosinase Human genes 0.000 claims description 21
- 108060008724 Tyrosinase Proteins 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 18
- 208000024891 symptom Diseases 0.000 claims description 14
- 239000006071 cream Substances 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 208000012641 Pigmentation disease Diseases 0.000 claims description 7
- 230000019612 pigmentation Effects 0.000 claims description 7
- 208000028990 Skin injury Diseases 0.000 claims description 6
- 206010008570 Chloasma Diseases 0.000 claims description 5
- 208000003351 Melanosis Diseases 0.000 claims description 5
- 230000001815 facial effect Effects 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 230000001629 suppression Effects 0.000 claims description 5
- 206010047642 Vitiligo Diseases 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000000551 dentifrice Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 235000013373 food additive Nutrition 0.000 claims description 3
- 239000002778 food additive Substances 0.000 claims description 3
- 230000000475 sunscreen effect Effects 0.000 claims description 3
- 239000000516 sunscreening agent Substances 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 description 41
- 238000011282 treatment Methods 0.000 description 27
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 21
- 238000012360 testing method Methods 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 230000002265 prevention Effects 0.000 description 17
- 101710147108 Tyrosinase inhibitor Proteins 0.000 description 14
- 239000001963 growth medium Substances 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- -1 Alkali metal cation Chemical class 0.000 description 6
- 239000006072 paste Substances 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- KJQFBVYMGADDTQ-CVSPRKDYSA-N L-buthionine-(S,R)-sulfoximine Chemical compound CCCCS(=N)(=O)CC[C@H](N)C(O)=O KJQFBVYMGADDTQ-CVSPRKDYSA-N 0.000 description 5
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 5
- 101710200814 Melanotropin alpha Proteins 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 210000002752 melanocyte Anatomy 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000012188 paraffin wax Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- 208000017520 skin disease Diseases 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000037303 wrinkles Effects 0.000 description 5
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 5
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 4
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000003405 delayed action preparation Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 3
- 241000222519 Agaricus bisporus Species 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 206010040829 Skin discolouration Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 3
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 3
- 229960004705 kojic acid Drugs 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000008099 melanin synthesis Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010048768 Dermatosis Diseases 0.000 description 2
- 235000002673 Dioscorea communis Nutrition 0.000 description 2
- 241000544230 Dioscorea communis Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 2
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 208000035753 Periorbital contusion Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 235000012055 fruits and vegetables Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical class CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 2
- 230000037307 sensitive skin Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- PJANXHGTPQOBST-VAWYXSNFSA-N trans-stilbene Chemical class C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 2
- 108010014402 tyrosinase-related protein-1 Proteins 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 1
- 150000005207 1,3-dihydroxybenzenes Chemical class 0.000 description 1
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- WHNCXIBKVUPNHR-UHFFFAOYSA-N 3,4-dihydroxy-1h-indole-2-carboxylic acid Chemical compound C1=CC(O)=C2C(O)=C(C(=O)O)NC2=C1 WHNCXIBKVUPNHR-UHFFFAOYSA-N 0.000 description 1
- YMGFTDKNIWPMGF-AGYDPFETSA-N 3-(3,4-dihydroxyphenyl)-2-[(e)-3-[2-[(e)-2-(3,4-dihydroxyphenyl)ethenyl]-3,4-dihydroxyphenyl]prop-2-enoyl]oxypropanoic acid Chemical compound C=1C=C(O)C(O)=C(\C=C\C=2C=C(O)C(O)=CC=2)C=1/C=C/C(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-AGYDPFETSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241001093575 Alma Species 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241001147468 Chondrus ocellatus Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001644525 Nastus productus Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 108010073443 Ribi adjuvant Proteins 0.000 description 1
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- 240000003864 Ulex europaeus Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- LLEMOWNGBBNAJR-UHFFFAOYSA-N biphenyl-2-ol Chemical compound OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- ZQNPDAVSHFGLIQ-UHFFFAOYSA-N calcium;hydrate Chemical compound O.[Ca] ZQNPDAVSHFGLIQ-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229950009789 cetomacrogol 1000 Drugs 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-L disulfate(2-) Chemical compound [O-]S(=O)(=O)OS([O-])(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-L 0.000 description 1
- 108010051081 dopachrome isomerase Proteins 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000000640 hydroxylating effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 150000002500 ions Chemical group 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 150000002672 m-cresols Chemical class 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229960003128 mupirocin Drugs 0.000 description 1
- 229930187697 mupirocin Natural products 0.000 description 1
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000003592 new natural product Substances 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 208000019180 nutritional disease Diseases 0.000 description 1
- 150000002883 o-cresols Chemical class 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000001835 salubrious effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N trans-Stilbene Chemical class C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a skin whitening and brightening compound and application thereof. The compound disclosed by the invention can be used for preparing a cosmetic composition for whitening and brightening skin.
Description
Technical field
The present invention relates to biological technical field, particularly relate to a kind of skin whitening lightening compounds and application thereof.
Background technology
Cutaneous visual appearance, physical property or physiological function a lot of because have, such as old and feeble, be exposed to hostile environment factor (such as ultraviolet radiation), nutritional disorder etc. for a long time. Change the most significantly and include the loss of the development of microgroove and wrinkle, elastic reduction, the reduction of consolidation, color homogeneity or tone, coarse superficial makings and mottled painted. Also include cell along with skin aging or the change experiencing long-term environmental nuisance and occur and the generally reduction of tissue activity, the reduction of cell replication rates, the minimizing of SkBF, moisture reduce, the 26S Proteasome Structure and Function of accumulation is lost and the decline of skin remodeling and self repair ability.
On visual appearance, one of significant change is the change of skin color. The color of application on human skin is by being positioned at melanic amount and type decided produced by the specialized cell melanocyte of skin base layer. Melanin is to be distributed one of natural pigment the most widely, and its structure complexity is the homogenizing polyphenol sample biopolymer that a kind of color changes from brown to black (eumelanin) and redness to yellow (pheomelanin). In human skin, melanin is considered to serve as the protective agent of ultra-violet radiation resisting.
Melanic excessive generation can cause different types of abnormal skin color, hair color and other dermatological conditions, for instance chloasma, senile plaque and photic damage site. Melanin is by originating in a series of oxidation reactions of amino acid tyrosine and polymerization procedure generation. Tryrosinase (EC1.14.18.1) is the type III enzyme comprising copper, it is two primary responses of catalysis in melanin produces: 1) by the vicinal hydroxyl groups of the TYR of single phenolase effect, and 2) by the oxidation of the 3,4-dihydroxyphenyl-L-alanine (L-DOPA) of two phenolase effects → o-DOPA quinone. Than previous step more faster, therefore the hydroxylating of tyrosine is considered as the rate-determing step in melanin biosynthesis to a rear oxidation step. O-DOPA quinone is converted into melanin by a series of enzymatics and non-enzymatic polyreaction subsequently. Such as dopachrome tautomerase (tyrosinase related protein1; And dihydroxy indole carboxylic acid (DICHA) oxidase (tyrosinase-related protein 1 TRP-2); TRP-1) other enzymes are also included within melanic biosynthetic process. Owing to tryrosinase plays the effect of key in the process that melanin produces, so the inhibitor of this enzyme is typically used as skin whitener.
Prior art has been described with the multiple tyrosinase inhibitor naturally occurring and synthesizing. Most compounds comprises phenol structure. These compounds serve as metal-chelator. The medicine comprising hydroquinone (2-4%) is effective for appropriateness, but hydroquinone is considered melanocyte is had cytotoxicity, and mammalian cell has potential mutagenicity. Many tyrosinase inhibitors are resorcinol derivatives or the polyphenol derivatives of flavonoid or trans-stilbene, for instance resveratrol or derivatives thereof. The compound of these types known and metal ion form strong chelate.
Although it have been reported that multiple compounds is effective tyrosinase inhibitor, but the character showing skin whitener considerably less in them. Further, it is found that most of poisonous in these reagent, or show the adverse side effect to people. Therefore, the research for having effective tyrosinase inhibitory activity and the low new natural product of cytotoxicity or synthesis compound is still continuing.
Summary of the invention
First purpose of the present invention is to provide a kind of skin whitening lightening compounds and application thereof.
The preparation method that second purpose of the present invention is to provide a kind of above-mentioned composition.
A first aspect of the present invention provides the compound shown in a kind of Formulas I or its pharmaceutically acceptable salt, the purposes in preparation compositions or medicine,
Described compositions or medicine are used for:
(1) tyrosinase activity is suppressed; And/or
(2) melanin is suppressed to produce; And/or
(3) prevent or treat the disease relevant with melanic excessive generation or skewness or symptom; And/or
(4) the brightening of skin or tooth; And/or
(5) blast of skin or tooth; And/or
(6) skin injury is repaired.
In another preference, described disease or symptom are selected from: tanned, cutaneous pigmentation, chloasma, vitiligo, and melanoma.
In another preference, described skin is mammal skin, and described mammal is preferably people.
In another preference, described compositions is used for preparing medicine, emulsion, cream for skin care, cream, essence, facial film, sunscreen cream, foundation cream or lip pomade, but the scope of the present invention is not limited to this.
In another preference, the invention provides the compound shown in a kind of Formulas I or its pharmaceutically acceptable salt, the purposes in the compositions or medicine of preparation suppression tyrosinase activity.
In another preference, the invention provides the compound shown in a kind of Formulas I or its pharmaceutically acceptable salt, the purposes in the compositions or medicine of preparation suppression melanin generation.
In another preference, the invention provides the compound shown in a kind of Formulas I or its pharmaceutically acceptable salt, the purposes in the compositions or medicine of preparation prevention or the treatment disease relevant with melanic excessive generation or skewness or symptom.
In another preference, the invention provides the compound shown in a kind of Formulas I or its pharmaceutically acceptable salt, the purposes in preparing the compositions for skin or teeth whitening and/or blast or medicine.
In another preference, the invention provides the compound shown in a kind of Formulas I or its pharmaceutically acceptable salt, the purposes in the compositions or medicine of preparation reparation skin injury.
A second aspect of the present invention provides a kind of compositions, the compound shown in the contained I of described compositions or its pharmaceutically acceptable salt and pharmaceutically acceptable carrier, and described compositions is used for,
(1) tyrosinase activity is suppressed; And/or
(2) melanin is suppressed to produce; And/or
(3) prevent or treat the disease relevant with melanic excessive generation or skewness or symptom; And/or
(4) the brightening of skin or tooth; And/or
(5) blast of skin or tooth; And/or
(6) skin injury is repaired.
In another preference, described compositions includes pharmaceutical composition, cosmetic composition, dentifrice composition, food additive, Halth-care composition etc.
In another preference, described carrier includes water, organic solvent etc.
In another preference, described cosmetic composition includes: emulsion, cream for skin care, cream, essence, facial film, sunscreen cream, foundation cream or lip pomade, but the scope of the present invention is not limited to this.
A third aspect of the present invention provides a kind of method suppressing tyrosinase activity, and described method includes step: contacted with formula I by tryrosinase, thus suppressing tyrosinase activity.
In another preference, described method is for the purpose of non-treatment.
A fourth aspect of the present invention provides a kind of prevention and the method treating the disease relevant with tyrosinase activity and disease condition, including step: inside or administer locally to the compound of formula I of the present invention of individual treatment effective dose in need.
A fifth aspect of the present invention provides a kind of method suppressing B16 cell in individuality in need, and described method includes the compound of formula I giving the present invention that this individuality uses effective dose.
Should be understood that within the scope of the present invention, above-mentioned each technical characteristic of the present invention and can combining mutually between specifically described each technical characteristic in below (eg embodiment), thus constituting new or preferred technical scheme. As space is limited, tired no longer one by one state at this.
Accompanying drawing explanation
Fig. 1 shows that tryrosinase is had inhibitory activity significantly by the compound of the present invention;
Fig. 2 shows the inhibition that melanin is produced by the compound of the present invention.
Detailed description of the invention
This application provides tryrosinase is had excellence inhibitory activity and low-down Cytotoxic compound. The present invention includes the pharmaceutically acceptable salt of this tyrosinase inhibitor. Present invention additionally comprises the pharmaceutical composition of tyrosinase inhibitor and at least one pharmaceutically acceptable carrier comprised to the present invention. The compositions of the present invention can be prepared with any suitable pharmaceutically acceptable dosage form.
Present invention also offers the method suppressing tryrosinase in individuality in need, described method includes the compositions giving the tyrosinase inhibitor comprising the present invention of effective dose.
Present invention also offers prevention and the method treating the disease relevant with tyrosinase activity and disease condition. The prevention of the present invention and the method for the treatment of include inside or administer locally to the tyrosinase inhibitor of the present invention of individual treatment effective dose in need.
Present invention also offers the method suppressing B16 cell in individuality in need. Such method includes the compositions giving the compound comprising the present invention of effective dose.
Present invention also offers prevention and the method treating the disease relevant with melanic excessive generation or skewness and disease condition, described method includes inside or administers locally to the compound of the present invention of individual treatment effective dose in need. The disease relevant with melanic excessive generation or skewness and disease condition include but not limited to the pigmentation speckle, chloasma, hepatopathy, thermal burn and the local wound that are caused by skin aging, the cutaneous pigmentation that the inflammatory conditions caused by fungus, microorganism and viral infection causes, vitiligo, tumor, melanoma and other mammal skin disease conditions. The skin that described method can be also used for prevention and treatment causes by exposure to the sun, ultraviolet (UV) radiation, chemicals, heat, wind and dry environment is dark-coloured and damages. Finally, described method may be used for prevention and treatment wrinkle, lax skin, the wrinkle of around eyes and black eye, lax sensitive skin and the dermatosis situation that prevention is relevant with other anaphylaxiss with treatment dermatitis.
In particular embodiments, giving the dosage of the tyrosinase inhibitor of the present invention of individuality in need is effectively nontoxic amount, and it is generally selected from: based on the 0.001% to 100% of the gross weight of final preparation; And/or based on every kilogram of 0.01mg to 200mg of whose body weight. Those skilled in the art use routine clinical test to may determine that the optimal dose for the specified disease being treated. The compositions of the present invention can be given by any method known to those skilled in the art. Administering mode includes but not limited to intestinal (being administered orally) administration, parenteral (intravenous, subcutaneous and intramuscular) administration and topical application. The Therapeutic Method of the present invention includes the compound of the present invention that is internal to patient in need or that administer locally to therapeutically effective amount. In preferred embodiments, described compositions is administered locally to.
In another embodiment, it is possible to the compound of the present invention is used in food industry to suppress brown stain and the variable color of water fruits and vegetables, juice and other food.
Although the method similar or suitable with those described herein and material may be used for practice or the test of the present invention, suitable method and material are still described below. All publicly available publication referred to herein, patent application, patent and other lists of references are incorporated herein by reference to the overall.
The invention provides salvianolic acid A or its pharmaceutically acceptable salt, the purposes in preparation compositions or medicine, described compositions or medicine are used for:
(1) tyrosinase activity is suppressed; And/or
(2) melanin is suppressed to produce; And/or
(3) prevent or treat the disease relevant with melanic excessive generation or skewness or symptom; And/or
(4) the brightening of skin or tooth; And/or
(5) blast of skin or tooth; And/or
(6) skin injury is repaired.
The invention provides the compound of the effective inhibitor as tryrosinase. Specifically, the invention provides the tyrosinase inhibitor with structure described in below formula I or its pharmaceutically acceptable salt,
This compound shows as the tyrosinase inhibitory activity and low cytotoxicity with excellence. Embodiment demonstrates the compound of formula I inhibitory activity to Mushroom Tyrosinase, and to melanic suppression produced by Mus B16-F1 melanoma cells. And the skin whitening character of representative compound is evaluated by the application on human skin model rebuild. These compounds or their pharmaceutically acceptable salt show as the cosmetics for being detailed below and medical application.
The preparation method of the compound shown in Formulas I is referred to method described in document Chinese patent application CN201310192210.0.
Various term used herein relates to the many aspects of the present invention. In order to help to set forth the description of instant component, it is provided that defined below. Unless otherwise defined, all technology used herein and scientific terminology have the implication that those skilled in the art in the invention are generally understood that.
As used herein, term " tyrosinase inhibitor ", " shown in Formulas I compound ", " present invention () compound " each mean the compound with structure shown in Formulas I.
As used in this article, " about " can be readily appreciated by one skilled in the art, and can be changed to a certain degree in the linguistic context that it is used. If in the linguistic context used by this given term, there is those skilled in the art the purposes of this term unclear, then " about " represent that being equal to this particular term adds or deduct 10%.
" treatment " used herein includes prevention (prevention), treatment and/or prevention (prophylaxis). When deployed, treatment refers to the mankind and other animals.
" medicine or therapeutically effective dosage or amount " refers to the dosage level being enough to induce desired biological results. Described result can be sign, symptom or disease reason alleviate or desired living things system any other change. Accurate dosage can change according to various factors, and described factor includes but not limited to Individual Age and the effect of size, disease and treatment.
" host " or " patient " or " individuality " are the mammal alive of expectation treatment, the mankind or animal. " host ", " patient " or " individuality " typically refers to the method according to the invention and implements the receptor for the treatment of. It should be noted that, invention as herein described may be used for veterinary and people's application, and term " host " should do not explained in a limiting fashion. When veterinary applies, dosage range can be as described below, it is considered to the body weight of animal is determined.
Term used herein " pharmaceutically acceptable " represents to be checked and approved or is listed in state-promulgated pharmacopoeia list or other pharmacopeia generally approved by federal or national authority for animal, and more specifically to the mankind. Term " carrier " refers to the diluent, adjuvant, excipient or the vehicle that give together with treating, and includes but not limited to such as water and oil sterile liquid.
" the pharmaceutically acceptable salt " of tyrosinase inhibitor or the product that " salt " is the compounds as disclosed herein containing ionic bond, it is suitable for giving individuality, and usually by making disclosed compound prepare with acid or alkali reaction. Pharmaceutically acceptable salt can include but not limited to acid-addition salts, and it includes hydrochlorate, hydrobromate, phosphate, sulfate, disulfate, alkylsulfonate, arylsulphonate, alkylaryl sulfonate, acetate, benzoate, citrate, maleate, fumarate, succinate, lactate and tartrate; Alkali metal cation, for instance Li, Na, K; Alkali salt, for instance Mg or Ca; Or organic amine salt.
" pharmaceutical composition " is for being suitable for administration to the preparation comprising disclosed compound of the form of individuality. Preferably the pharmaceutical composition of the present invention is formulated as route of administration desired with it compatible. The example of route of administration includes but not limited to oral and parenteral, for instance intravenous, Intradermal, subcutaneous, suck, locally, transdermal, saturating mucosa and rectally.
The present invention includes the pharmaceutical composition comprising at least one tyrosinase inhibitor as herein described. The compositions of the present invention can be formulated as the pharmaceutical composition comprising other components, these other components acceptable excipient of such as pharmacy and/or cosmetics, adjuvant and/or carrier. For example, it is possible to the compositions of the present invention is formulated in the tolerable excipient of the host to treat. Excipient is the inert substance of diluent or the vehicle being used as therapeutic agent. The example of such excipient includes but not limited to water, buffer, saline, Ringer's mixture (Ringer ' ssolution), glucose solution, mannitol, hanks solution (Hank ' ssolution), preservative and other aqueous physiological balanced salt solutions. Non-aqueous vehicles can also be used, for instance fixed oil, Oleum sesami, ethyl oleate or triglyceride. Other useful preparations include the suspension containing viscosity intensifier, and described viscosity intensifier is sodium carboxymethyl cellulose, Sorbitol or glucosan such as. Excipient can also contain a small amount of additive, for instance strengthens the material of isotonicity and chemical stability. The example of buffer includes phosphate buffer, bicarbonate buffer, tris buffer, histidine, citrate and glycine or their mixture, and the example of preservative includes but not limited to EDTA, EDETATE SODIUM, BHA, BHT, vitamin C, vitamin E, sodium sulfite, SnCl2, thimerosal, m-or o-cresols, formalin and benzylalcohol. Standard preparation can be liquid or solid, and it can be absorbed by the suitable liquid form of the suspension for being administered or solution. Therefore, in non-liquid formulation, excipient can comprise glucose, human serum albumin, preservative etc., it is possible to is added to sterilized water or saline before administration.
In an embodiment of the present invention, compositions can also include adjuvant or carrier. Generally, adjuvant is generally strengthen host's material to the biological answer-reply of particular bioactive agent. Suitable adjuvant includes but not limited to Freund adjuvant; Other bacterial cell wall components; Salt based on aluminum, magnesium, copper, zinc, ferrum, calcium and other metal ions; Silicon dioxide; Polynucleotide; Toxoid; Serum albumin; Virus capsid protein; The prepared product (preparation) of other bacterial origins; IFN-γ; Block copolymer adjuvants, for instance Hunter ' sTitermax adjuvant (Vaxcel.TM., Inc.Norcross, Ga.); Ribi adjuvant (from RibiImmunoChemResearch, Inc., Hamilton, Mont.); And saponin and their derivant, for instance QuilA (from SuperfosBiosectorA/S, Denmark). Carrier is generally increases the compound of therapeutic combination half-life in the host treated. Suitable carrier includes but not limited to polymeric controlled release preparation, biodegradable implant, liposome, antibacterial, virus, oil, ester and glycol. Suitable carrier is described in LippincottWilliams&Wilkins " Remington:TheScienceandPractice, the TwentiethEdition " published, and it is hereby incorporated herein by.
In one embodiment, being controlled release preparation by compositions preparation, the compositions of the present invention is discharged to host by lentamente. As it is used herein, controlled release preparation comprises the compositions of the present invention in controlled release vehicles thing. Suitable controlled release vehicles thing is that those skilled in the art are known. Preferred controlled release preparation is biodegradable (getting final product bio-digestion).
The compositions of the present invention can be given by any method known to those skilled in the art. Administering mode includes but not limited to intestinal (being administered orally) administration, parenteral (intravenous, subcutaneous and intramuscular) administration and topical application. The Therapeutic Method of the present invention includes the compound of the present invention that is internal to patient in need or that administer locally to therapeutically effective amount.
In one embodiment, being given the therapeutic agent of the present invention partly by any appropriate method for administering locally to therapeutic combination well known by persons skilled in the art, described therapeutic agent includes but not limited to ointment, gel, lotion or emulsifiable paste matrix; Or as toothpaste, collutory or coating on flossing material or as Emulsion, the therapeutic agent giving the present invention as patch, dressing or facial film (mask), inadhesive gauze, binder, swab or cleaning wiping cloth partly.
According to medication, it is possible to give therapeutic combination with various unit dosage forms. For the ad hoc fashion delivered, it is possible to the therapeutic combination of the present invention is formulated in the excipient of the present invention. Any host can be given, it is preferable that mammal by the treatment reagent of the present invention, and more preferably people. The ad hoc fashion of administration depends on the disease condition to treat.
In one embodiment, suitable ointment packets is containing the compound of the present invention of expectation concentration, and it is effectively nontoxic amount, and this amount is generally selected from 0.001% to 100% based on topical formulations gross weight; The White soft paraffin of 65% to 100% (preferably 75% to 96%); The liquid paraffin of 0% to 15%; And the lanoline or derivatives thereof of 0% to 7% (preferably 3% to 7%) or synthesis equivalent. In another embodiment, emulsifiable paste can comprise polyethylene-liquid paraffin substrate.
In one embodiment, suitable emulsifiable paste comprises the emulsification system together with at least one compound of the present invention presented above of expectation concentration. Emulsification system preferably comprises the polyoxyethylene alcohol of 2% to 10% (such as with trade name CetomacrogolTM1000 provide mixture), the stearyl alcohol of 10% to 25%, the liquid paraffin of 20% to 60% and 10% to 65% water; And one or more preservative, the N of such as 0.1% to 1%; N "-di-2-ethylhexylphosphine oxide [N '-[3-(methylol)-2,5-dioxy-4-imidazolidinyl] urea] (providing with the title of ImidureaUSNF), the 4-HBA Arrcostab mixture of Nipastat (commodity such as provided by NipaLaboratories by name) of 0.1% to 1%, the 4-HBA butyl ester sodium (being provided by NipaLaboratories, commodity are called Nipabutylsodium) of 0.01% to 0.1% and 0.1% to 2% phenyl phenol.
In one embodiment, suitable gel comprises semisolid systems, and wherein liquid phase is limited to and has in highly cross-linked three dimensional polymeric matrix. Liquid phase can comprise water; And the compound of the present invention of desired amount; Water-blendable the additive of such as glycerol, Polyethylene Glycol or the propylene glycol of 0% to 20%; With 0.1% to 10%, preferably 0.5% to 2% thickening agent, it can be the natural product selected from the group including but not limited to Tragacanth, pectin, chondrus ocellatus Holmes, agar and alginic acid, or is selected from the synthesis of the group including but not limited to methylcellulose and carbopol (Carbopol) or semi-synthetic compound; One or more preservative additional, it is selected from including but not limited to the 4-HBA methyl ester (methyl butex) of such as 0.1% to 2% or the group of phenyl phenol-different (differential). Another suitable substrate comprises the compound of the present invention of desired amount; And the Polyethylene Glycol of 70% to 90% (the Polyethylene Glycol emulsifiable paste containing 40% PEG3350 and 60% PEG400 such as prepared according to American National formulary (U.S.NationalFormulary) (USNF)), the water of 5% to 20%, the antioxidant (such as, butylated hydroxy-methylbenzene) of 0.02% to 0.25% and 0.005% to 0.1% chelating agen (such as ethylenediaminetetraacetic acid (EDTA)).
Term soft paraffin used above includes emulsifiable paste or ointment base White soft paraffin and yellow soft paraffin. Term lanoline includes the lanoline of natural wool fat and purification. The derivant of lanoline includes through chemical modification especially to change their lanoline physically or chemically; And the synthesis equivalent of lanoline includes synthesis or semi-synthetic compound and mixture especially, and it is known and is used as the alternative of lanoline in pharmacy and cosmetic field, and can such as be called lanoline substitute.
A kind of suitable synthesis equivalent of operable lanoline is with trade name SoftisanTMThe material being called Softisan649 provided. The Sofisan649 provided by DynamitNobelAktiengesellschaft is the glyceride of natural vegetable fatty acids, isostearic acid and adipic acid; H.Hermsdorf, in Fette, Seifen, Anstrichmittel, IssueNo.84, No.3 (1982), discusses their character in pp.3-6. Above-mentioned other materials as suitable ointment or emulsifiable paste matrix composition and their character are discussed in the work of the Standard reference works of such as pharmacopeia. Cetomacrogol 1000 is formula CH3(CH2)m(OCH2CH2)nOH, wherein m can be 15 or 17, and n can be 20 to 24. Butylated hydroxy-methylbenzene is 2,6-di-t-butyl-paracresol. Nipastat is the mixture of 4-HBA methyl ester, 4-HBA ethyl ester, 4-HBA propyl ester and 4-HBA butyl ester.
The compositions of the present invention can be prepared by conventional phamaceutical techniques. Therefore, above-mentioned composition such as can by mixing soft paraffin at the rising temperature of preferred 60-70 DEG C jointly; Liquid paraffin, if existing; And lanoline or derivatives thereof or synthesis equivalent prepare easily. Mixture can be cooled to room temperature subsequently, and after adding the crystalline hydrate calcium salt of mupirocin and corticosteroid and any other composition, stir fully dispersed to guarantee.
The mode no matter being administered, calculates concrete dosage according to the substantially body weight of host. Improving further of calculating needed for determining the suitable dose of the treatment relating to every kind of above-mentioned preparation is made routinely by those skilled in the art, and without inappropriate experiment in the scope of the normal work to do carried out at them, in particular according to dosage information disclosed herein and mensuration. These dosage can by using for determining that the mensuration set up of dosage is determined with suitable dose response data coupling.
Known synthetic method can be utilized or via the improvement of known synthetic method to be easily synthesized the tyrosinase inhibitor of the present invention. As those skilled in the art easily recognize, following method allows synthesis to have the compound of multiple substituent group. The method that the present invention includes synthesizing compound as herein described. Exemplary synthetic procedure is described in example 1 below-5.
The present invention includes the method by using compound disclosed in one or more to prevent or to treat (such as alleviating one or more symptoms) medical conditions situation. Prevention or Therapeutic Method include the tyrosinase inhibitor giving the present invention of therapeutically effective amount to patient in need. The compositions of the present invention can be also used for prophylactic treatment.
The invention provides by suppressing tyrosinase activity or melanic excessive generation to improve the ill disease of institute thus treating individual method. Such method includes the tyrosinase inhibitor as herein described giving individual treatment effective dose.
" treatment " used herein describes for the purpose of Fighting Disease, disease condition or disease, process and treatment to patient, and including giving the compound of the present invention to prevent the generation of symptom or complication, relief of symptoms or complication, or eliminate a disease, disease condition or disease. More specifically, " treatment " includes reversion, alleviates, reduces, suppresses or stop at least one ill symptoms or the impact of disease (disease) state, progression of disease or other aberrant disease conditions. Continued treatment is until symptom and/or pathology improve.
More specifically, present invention also offers the method suppressing B16 cell in individuality in need. Such method includes the compositions giving the compound comprising the present invention of effective dose.
Present invention also offers prevention and the method treating the disease relevant with melanic excessive generation or skewness and disease condition, described method includes inside or administers locally to the Compound Compound of the present invention of individual treatment effective dose in need. The disease relevant with melanic excessive generation or skewness and disease condition include but not limited to the pigmentation speckle, chloasma, hepatopathy, thermal burn and the local wound that are caused by skin aging, the cutaneous pigmentation that the inflammatory conditions caused by fungus, microorganism and viral infection causes, vitiligo, cancer, melanoma and other mammal skin disease conditions.
The skin that described method can be also used for prevention and treatment causes by exposure to the sun, ultraviolet (UV) radiation, chemicals, heat, wind and dry environment is dark-coloured and damages. Finally, described method may be used for prevention and treatment wrinkle, lax skin, the wrinkle of around eyes and black eye, and lax sensitive skin is, and the prevention dermatosis situation relevant with other anaphylaxiss with treatment dermatitis.
Purposes except they preventions and treatment skin disease as above and disease condition, therapeutic combination as herein described provides effective compositions, which give following benefit: there is aging, the young outward appearance that strengthens and the structure of the colour of skin of improvement, the elasticity of enhancing, minimizing and delay and the pliability strengthened, hardness, smoothness and adaptive smooth and young skin appearance.
Still in another embodiment, the compound derivatives of the present invention may be used for food industry to suppress brown stain in water fruits and vegetables, juice and other food and variable color.
Below in conjunction with specific embodiment, the present invention is expanded on further. Should be understood that these embodiments are merely to illustrate the present invention rather than restriction the scope of the present invention. The experimental technique of unreceipted actual conditions in the following example, generally conventionally condition, such as Sambrook et al., molecular cloning: laboratory manual (NewYork:ColdSpringHarborLaboratoryPress, 1989) condition described in, or according to manufacturer it is proposed that condition. Unless otherwise indicated, otherwise percentage ratio and number are percentage by weight and parts by weight.
Material used in following example all can obtain from commercially available channel, and wherein, Agaricus bisporus (Agaricusbisporus) tryrosinase is purchased from Sigma-Aldrich company (T3824-50KU); S91melanoma cell B16-F1 is purchased from ATCC (CRL-6323); People's neonate dermal fibroblast is purchased from wonderful logical (Shanghai) bio tech ltd (2310). Method described in Chinese patent application CN201310192210.0 is adopted to prepare the compound shown in Formulas I.
Embodiment 1 measures tyrosinase inhibitory activity
To mix containing different 60 μ L sample of test compounds substrate concentration and the phosphate buffer (pH6.8) containing 1mML-tyrosine of 100 μ L. Then, add 40 μ L Agaricus bisporus tryrosinase (100U/mL), hatch 25 minutes for 37 DEG C.
Absorbed the accumulation monitoring color products (dopachrome) by the light at 450nm place, calculate tyrosinase inhibition rate (dopachrome suppression ratio). Without in the matched group of testing compound, tyrosinase inhibition rate is 0.
Result
Often group test carries out in triplicate, and experimental result is as it is shown in figure 1, show in Fig. 1 that tryrosinase is had inhibitory activity significantly, IC by the compound of the present invention50Value is about 8mM.
Embodiment 2 melanin generates inhibition experiment
In the cell growth medium of 100 μ l, with 2 × 105B16-F1 cell is seeded on 96 hole flat boards of clear bottom by cells/well.
Cell culture condition: DMEM/ high glucose, is supplemented with the streptomycin of glutamine, Sodium Pyruvate, the hyclone of 10% dialysis, 1% non essential amino acid, the penicillin of 50 units/mL and 50 μ g/mL; 37 DEG C, 95% air and 5%CO2。
Within second day, in cell culture fluid, add testing compound, the final concentration of testing compound respectively 1 μM, 10 μMs, 100 μMs and 1000 μMs, be subsequently adding the α-MSH of 100nM, cell is kept 24 hours at 37 DEG C. After cultivation completes, the 1NNaOH adding 120 μ L dissolves melanin 1h at 65 DEG C. Then melanic content is detected under 405nm absorbance again.
Result
Often group test carries out in triplicate, experimental result is as shown in Figure 2, under the stimulation of α-MSH, the melanin production of B16-F1 cell significantly improves, and it is simultaneously introduced in the experimental group of α-MSH and the compounds of this invention, melanic yield substantially reduces, and shows the inhibition that melanin is produced by the compound of the present invention in Fig. 2, does not wherein add α-MSH and testing compound in matched group. Depositing in case at the compounds of this invention of 100 μMs, compared with the experimental group that only with the addition of α-MSH, melanin production reduces about 40%.
Embodiment 3 skin lightening effects is tested
Utilize and rebuild skin model (purchased from MatTek company, MelanodermTM) research testing compound skin lightening effects.
Co-culture on the surface of film of coating collagen protein from Normal human epidermal's keratinocyte of dark skin donor and normal person's melanocyte to form multilamellar, well differentiated skin histology. This tissue is maintained at the CO of 37 DEG C2In incubator. The top surface rebuilding skin is exposed in air, and lower surface still maintains culture medium with the 5mL containing the skin differentiation factor (EPI-100-NNM-113) and contacts.
Test compound is formulated in the aqueous solution of propylene glycol of 80%: 10mg every kind is tested compound and is dissolved in 1mL propylene glycol, 0.2 μm of filter is degerming, and to be diluted to ultimate density in sterilized water/propylene glycol be 0.1% (w/v), 0.2% (w/v) and 0.4% (w/v). The concentration of propylene glycol in all samples is maintained at 80%. Matched group is respectively as follows: 1% kojic acid in sterilized water, 80% propylene glycol and water.
Test compound is applied to the surface of cultured tissue: 1% kojic acid (positive control) of the testing compound of 10 μ l, 80% propylene glycol (vehicle control) of 10 μ l, the sterilized water (negative control) of 25 μ l and 25 μ l. Every other day using once, continue 15 days, all samples is tested in duplicate.
Result
In rebuilding skin model, the skin lightening effects of compound is tested in research further. This model is made up of normal people source epidermal keratinocytes and melanocyte, co-cultures them to form multilamellar, well differentiated people's epidermis. In this study, highly Pigmented donor melanocyte is obtained.
By variable concentrations test compound, 80% propylene glycol (vehicle control), water (negative control) or 1% kojic acid (positive control) repeatedly be applied topically to rebuild skin surface, continue 15 days. Found that use the compounds of this invention of 0.2% concentration can show the significant whitening effect of dermal melanin cell, without causing any detectable change of cellular morphology. After experiment starts, 0.2% concentration experiment group can be observed the obvious effect brightened to skin model at the 5th day, and namely 0.4% concentration experiment group can be observed the effect brightened to skin model at the 3rd day.
Embodiment 4 prevents ultraviolet injury from testing
Cell is cultivated
Cell uses commercially available people's neonate dermal fibroblast. Described cell is with 2 × 105Individual/mL is inoculated in culture dish, adds 10% hyclone (culture medium I) and cultivate in culture medium D-MEM (1g/L glucose). Condition of culture is, 37 DEG C, 5%CO2And cultivate 24 hours when saturated steam.
Then, culture medium is replaced by BSO culture medium (medium ii), it is added with the BSO (L-buthionine-(S, R)-sulfoximine) of the biosynthesis inhibitor as glutathion of 0.001%, at 37 DEG C, 5%CO2And cultivate 24 hours when saturated steam. Described BSO culture medium is prepared as follows: in described ordinary culture medium, the preservation stock solution being dissolved with 0.1%BSO in ethanol is diluted 100 times.
Before irradiation ultraviolet radiation 24 hours, it is replaced by the BSO culture medium (medium ii) of the compounds of this invention solution being added with 100 μ L. Using without compound as negative control.
Iron chloride is dissolved in distilled water according to the concentration of 0.002% (weight), with containing calcium ion, magnesium ion phosphate buffer PBS (+) dilution 200 times after, as medium ii I, be previously heated to 37 DEG C standby.
Before irradiating UV-A, culture medium is replaced into medium ii I. When removing culture dish lid, from the about 30cm in the top of culture dish, with 10J/cm2Irradiate the ultraviolet of 320nm to 400nm. Positive control is irradiation ultraviolet radiation not, and the living cell rate taking positive controls is 100%.
Then, in culture medium, ALMA blue (alamarBlue) is added according to the mode that ultimate density is 10%, after 3 hours, measure the fluorescence intensity of supernatant according to the methods of (J.Immunol.Method.170,211-224 (1994)) such as AhmedS.A. and the description of manufacturer with excitation wavelength 544nm, wavelength of fluorescence 590nm and calculate living cell rate (%).
Table 2 prevents ultraviolet injury from testing
| Sample | Living cell rate (%) |
| Positive control | 100 |
| Negative control | 38 |
| A | 54 |
| B | 68 |
| C | 70 |
| D | 73 |
| E | 76 |
In experimental group A-F, the final concentration of testing compound respectively 4mM, 8mM, 16mM, 32mM, 64mM in test system.
As can be known from the above results, the compounds of this invention can be obviously enhanced cell to ultraviolet tolerance level, by increasing capacitance it is possible to increase living cell rate, alleviates cell death. Compared with negative control group, the living cell rate of 30% can be improved under 8mM concentration.
The preparation of embodiment 5 cosmetic composition
Composition preparing cosmetics compositions shown according to the form below, in table, each component is parts by weight. It is first according to the proportioning in following table formulation components I, II and III respectively, then component I, II and III stirring is mixed and obtains cosmetic composition. The white translucent thick liquid nano of this cosmetic composition, the frivolous water profit of quality, abnormal smells from the patient is pure and fresh. Without greasy feeling during use, ductility is good, absorbs rapidly, uses the salubrious water of rear skin to run through bright.
Can obviously improve the phenomenon such as facial lines, dim mute, pigmentation, cutis laxa, corse sweat pore, blackhead after life-time service, skin of face is pale, water is tender, fine and smooth, compact, smooth, the colour of skin is homogeneous bright. This cosmetic composition texture and skinfeel after stability test is unchanged, has good stability.
The preferred embodiment of the present invention described in detail above. Should be appreciated that those of ordinary skill in the art just can make many modifications and variations according to the design of the present invention without creative work. Therefore, all technical staff in the art, all should in the protection domain being defined in the patent claims under this invention's idea on the basis of existing technology by the available technical scheme of logical analysis, reasoning, or a limited experiment.
Claims (10)
1. the compound shown in Formulas I or its pharmaceutically acceptable salt, the purposes in preparation compositions or medicine, it is characterised in that
I;
Described compositions or medicine are used for:
(1) tyrosinase activity is suppressed; And/or
(2) melanin is suppressed to produce; And/or
(3) prevent or treat the disease relevant with melanic excessive generation or skewness or symptom; And/or
(4) the brightening of skin or tooth; And/or
(5) blast of skin or tooth; And/or
(6) skin injury is repaired.
2. purposes as claimed in claim 1, wherein, described disease or symptom are selected from: tanned, cutaneous pigmentation, chloasma, vitiligo, and melanoma.
3. purposes as claimed in claim 1, wherein, described skin is mammal skin, and described mammal is preferably people.
4. purposes as claimed in claim 1, wherein, described compositions includes pharmaceutical composition, cosmetic composition, dentifrice composition, food additive, Halth-care composition etc.
5. the compound shown in Formulas I or its pharmaceutically acceptable salt, the purposes in the compositions or medicine of preparation suppression tyrosinase activity
I。
6. a compositions, the compound shown in the contained I of described compositions or its pharmaceutically acceptable salt and pharmaceutically acceptable carrier, described compositions is used for,
(1) tyrosinase activity is suppressed; And/or
(2) melanin is suppressed to produce; And/or
(3) prevent or treat the disease relevant with melanic excessive generation or skewness or symptom; And/or
(4) the brightening of skin or tooth; And/or
(5) blast of skin or tooth; And/or
(6) skin injury is repaired;
I。
7. compositions as claimed in claim 1, wherein, described compositions includes pharmaceutical composition, cosmetic composition, dentifrice composition, food additive, Halth-care composition etc.
8. compositions as claimed in claim 7, wherein, described cosmetic composition includes: emulsion, cream for skin care, cream, essence, facial film, sunscreen cream, foundation cream or lip pomade.
9. the method suppressing tyrosinase activity, wherein, described method includes step: contacted with formula I by tryrosinase, thus suppressing tyrosinase activity.
10. the method suppressing B16 cell in individuality in need, wherein, described method includes the compound of formula I giving the present invention that this individuality uses effective dose.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410655197.2A CN105662903A (en) | 2014-11-17 | 2014-11-17 | Skin whitening and brightening compound and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410655197.2A CN105662903A (en) | 2014-11-17 | 2014-11-17 | Skin whitening and brightening compound and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105662903A true CN105662903A (en) | 2016-06-15 |
Family
ID=56944068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410655197.2A Pending CN105662903A (en) | 2014-11-17 | 2014-11-17 | Skin whitening and brightening compound and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105662903A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116585335A (en) * | 2023-06-07 | 2023-08-15 | 广东植肤生物科技有限公司 | A skin external composition for inhibiting TYR activity and MC1R expression |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102827002A (en) * | 2012-05-29 | 2012-12-19 | 北京正大绿洲医药科技有限公司 | Chemical full-synthetic method of salvinanolic acid A |
| CN102895308A (en) * | 2012-11-13 | 2013-01-30 | 孙海峰 | New application of B Salvianolic acid taken as cosmetics additives with functions of whitening skin, removing freckle and resisting wrinkle |
-
2014
- 2014-11-17 CN CN201410655197.2A patent/CN105662903A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102827002A (en) * | 2012-05-29 | 2012-12-19 | 北京正大绿洲医药科技有限公司 | Chemical full-synthetic method of salvinanolic acid A |
| CN102895308A (en) * | 2012-11-13 | 2013-01-30 | 孙海峰 | New application of B Salvianolic acid taken as cosmetics additives with functions of whitening skin, removing freckle and resisting wrinkle |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116585335A (en) * | 2023-06-07 | 2023-08-15 | 广东植肤生物科技有限公司 | A skin external composition for inhibiting TYR activity and MC1R expression |
| CN116585335B (en) * | 2023-06-07 | 2024-02-09 | 广东植肤生物科技有限公司 | A skin external composition for inhibiting TYR activity and MC1R expression |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101823036B1 (en) | Inhibitor of melanin synthesis and the cosmetic composition containing the same | |
| US7381427B2 (en) | Seborrheic keratosis treatment | |
| US8758809B2 (en) | Skin treatment compositions containing copper-pigment complexes | |
| RU2764769C2 (en) | Products for external application with a two-phase system | |
| JP2005509660A (en) | Composition comprising ethanolamine derivative and organometallic salt | |
| KR101516074B1 (en) | Compositions comprising Polydatin and Tranexamic acid for whitening | |
| WO2016002767A1 (en) | Composition for external application | |
| JP2016511236A (en) | Skin whitening method using canola extract | |
| CN109348703A (en) | Composition containing ionone or a salt thereof as an active ingredient with effects of improving skin moisturizing, exfoliating skin, enhancing skin elasticity, inhibiting erythema, improving skin wrinkles, or improving skin photoaging | |
| CN108815013A (en) | A kind of skin care whitening stoste and its promote to seep technical application in skin | |
| ES2714075T3 (en) | Dermatological kit comprising compositions based on hibiscus flower and buriti oil | |
| MXPA05001954A (en) | Compositions and methods for treating skin conditions. | |
| JPWO2016121962A1 (en) | Melanin production inhibitor | |
| CN105662903A (en) | Skin whitening and brightening compound and application thereof | |
| CN113693966A (en) | Innovative whitening brightening freckle-removing cream and preparation method thereof | |
| CN105662904A (en) | Melanogenesis inhibitor and applications thereof | |
| KR100843155B1 (en) | Double-stabilized Vitamin C-containing skin whitening cosmetic composition | |
| JP2000344653A (en) | Eraser for active oxygen and skin cosmetic | |
| US8217074B2 (en) | Use of sargachromenol | |
| CN105596322A (en) | Tyrosinase inhibitor and applications thereof | |
| US20180185259A1 (en) | Methods of treating hyperpigmentation disorders | |
| JPH09175983A (en) | External preparation for skin | |
| JP4842550B2 (en) | Tyrosinase activity inhibitor, melanin production inhibitor, and skin whitening external preparation | |
| CN119523962B (en) | Application of chlorogenic acid and blue light in the preparation of anti-photoaging products and thermosensitive transdermal delivery hydrogel loaded with chlorogenic acid | |
| JP2003321463A (en) | Skin care preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160615 |